TNF Pharmaceuticals Files 8-K for Bylaw Amendments & Exhibits
Ticker: QCLS · Form: 8-K · Filed: May 9, 2025 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | May 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filings, exhibits
TL;DR
TNF Pharma filed an 8-K for bylaw changes and financial docs. No major business updates.
AI Summary
On May 9, 2025, TNF Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws and the submission of financial statements and exhibits. The company, formerly known as MyMD Pharmaceuticals, Inc., is incorporated in Delaware and has its principal business address in New York.
Why It Matters
This 8-K filing indicates potential corporate governance changes and the submission of important financial and operational documents for TNF Pharmaceuticals, Inc.
Risk Assessment
Risk Level: low — The filing is procedural, detailing amendments and exhibit submissions without announcing significant financial events or strategic shifts.
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Registrant
- May 9, 2025 (date) — Date of earliest event reported
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- Akers Biosciences, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Business address city
FAQ
What specific amendments were made to the Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text excerpt. The full filing would contain this information.
What financial statements and exhibits are being filed with this 8-K?
The filing states that Financial Statements and Exhibits are being filed, but the specific list or content of these documents is not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 9, 2025.
What is the SIC code for TNF Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for TNF Pharmaceuticals, Inc. is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
What were TNF Pharmaceuticals, Inc.'s previous names?
TNF Pharmaceuticals, Inc. was previously known as MyMD Pharmaceuticals, Inc. (name change on 20210420) and Akers Biosciences, Inc. (name changes on 20170413 and 20050325).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 9, 2025 regarding TNF Pharmaceuticals, Inc. (QCLS).